Clinical Trial of Autologous CD19 CAR-T Cells (CNCT19) Therapy for Advanced Hepatocellular Carcinoma

This study tests an experimental CAR-T cell therapy — where immune cells from your own blood are engineered in a lab to attack cancer — in people with advanced liver cancer (hepatocellular carcinoma). The engineered cells target a protein called CD19 found on certain cancer cells. **You may be eligible if...** - You are 18–80 years old - You have a confirmed diagnosis of hepatocellular carcinoma (liver cancer) - Your cancer is at an advanced stage (stage IIIa or beyond) - You have received or are ineligible for standard treatments - Your liver function and overall health meet the study requirements **You may NOT be eligible if...** - You have received prior CAR-T cell therapy - You have severe liver failure or other major organ problems - You have active serious infections - You are pregnant or breastfeeding - You have autoimmune disease requiring treatment Talk to your doctor to see if this trial is right for you.